CellDetect® Cervical

Cervical Cancer is the fourth most common cause of cancer death in women worldwide. There are over half a million new cases diagnosed each year, 85% of which in developing regions.

CellDetect Cervical offers a new standard for the screening of women at risk of developing cervical cancer. Designed to simplify and expedite the microscopic examination of cervical smears while relying on standard lab equipment and processes, CellDetect addresses key
unmet needs in markets where cervical cancer still represents a significant healthcare burden.

CellDetect Cervical is approved in Europe, Israel and China. Micromedic is currently performing pilots in India and other territories.


Aqarwal et al. Evaluation of CellDetect
® for cervical cancer screening in a reference cytology laboratory in India. Poster presented at USCAP annual meeting in Vancouver, March 2018

He et al. Application of the CellDetect® staining technique in diagnosis of human cervical cancer. Gynecologic Oncology 2014; 132:383-388

Idelevich et al. Screening for cervical neoplasia: a community-based trial comparing pap Staining, Human Papilloma Virus Testing, and the New Bi-functional CellDetect® Stain. Diagnostic Cytopathology 2012; 40:1054-61

Idelevich et al. Novel dual-function CellDetect® staining technology: wedding morphology and tinctorial discrimination to detect cervical neoplasia; Diagnostic Pathology 2010; 5:70


© Micromedic Technologies Ltd. site mapcontact
Site by Site2goal | Design Studio Michal Lehavi